Article
Low-activity V89L variant in SRD5A2 is associated with aggressive prostate cancer risk: an explanation for the adverse effects observed in chemoprevention trials using 5-alpha-reductase inhibitors.
European urology - 1 Oct 2007
Cussenot Olivier, Azzouzi Abdel-Rahmène, Nicolaiew Nathalie, Mangin Philippe, Cormier Luc, Fournier Georges, Valeri Antoine, Cancel-Tassin Géraldine
Abstract excerpt
OBJECTIVE: The 5-alpha-reductase type 2 (5A2) enzyme catalyses the irreversible conversion of testosterone to dihydrotestosterone, the most active androgen in the prostate. This key enzyme in prostate gland physiopathology has recently been targeted by using inhibitors for chemoprevention of pros...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.